TransMedics Group (NASDAQ:TMDX) Shares Up 8.8% – Still a Buy?

TransMedics Group, Inc. (NASDAQ:TMDX)’s stock price rose 8.8% during trading on Wednesday . The stock traded as high as $128.02 and last traded at $127.3810. Approximately 323,007 shares changed hands during trading, a decline of 74% from the average daily volume of 1,223,270 shares. The stock had previously closed at $117.07.

Analyst Ratings Changes

A number of equities analysts have commented on TMDX shares. Piper Sandler cut their price objective on shares of TransMedics Group from $145.00 to $140.00 and set an “overweight” rating on the stock in a report on Thursday, October 30th. Needham & Company LLC reaffirmed a “buy” rating on shares of TransMedics Group in a report on Thursday, October 30th. Morgan Stanley increased their price objective on shares of TransMedics Group from $115.00 to $123.00 and gave the stock an “equal weight” rating in a report on Friday, August 1st. Wall Street Zen upgraded shares of TransMedics Group from a “hold” rating to a “buy” rating in a research report on Saturday, October 18th. Finally, Canaccord Genuity Group lifted their price target on TransMedics Group from $142.00 to $147.00 and gave the company a “buy” rating in a report on Thursday, October 30th. Seven research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $131.80.

TransMedics Group Trading Up 10.9%

The company has a market cap of $4.44 billion, a P/E ratio of 52.21 and a beta of 2.05. The firm’s 50 day moving average is $119.16 and its two-hundred day moving average is $120.33. The company has a quick ratio of 7.13, a current ratio of 7.69 and a debt-to-equity ratio of 1.43.

TransMedics Group (NASDAQ:TMDX) last posted its quarterly earnings results on Wednesday, October 29th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.37 by $0.29. TransMedics Group had a return on equity of 31.42% and a net margin of 16.20%.The firm had revenue of $143.82 million for the quarter, compared to analysts’ expectations of $145.33 million. During the same period in the prior year, the business earned $0.12 EPS. The company’s revenue for the quarter was up 32.2% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Buying and Selling at TransMedics Group

In other news, Director Edward M. Basile sold 4,142 shares of TransMedics Group stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $130.45, for a total transaction of $540,323.90. Following the completion of the transaction, the director directly owned 2,866 shares in the company, valued at $373,869.70. This trade represents a 59.10% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 7.00% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in TMDX. Advisory Services Network LLC bought a new stake in shares of TransMedics Group in the 3rd quarter worth approximately $274,000. Dark Forest Capital Management LP lifted its stake in TransMedics Group by 415.1% during the 3rd quarter. Dark Forest Capital Management LP now owns 29,405 shares of the company’s stock valued at $3,299,000 after acquiring an additional 23,696 shares during the period. PharVision Advisers LLC increased its position in TransMedics Group by 95.0% during the third quarter. PharVision Advisers LLC now owns 3,841 shares of the company’s stock valued at $431,000 after acquiring an additional 1,871 shares during the last quarter. Zurich Insurance Group Ltd FI bought a new stake in shares of TransMedics Group during the 3rd quarter valued at $2,356,000. Finally, Quarry LP lifted its holdings in TransMedics Group by 41.9% during the third quarter. Quarry LP now owns 959 shares of the company’s stock valued at $108,000 after purchasing an additional 283 shares in the last quarter. Institutional investors own 99.67% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.